CD437 is a specifc Retinoic Acid Receptor γ (RARγ) agonist.

＞98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

Solid

AHPN；CD 437；CD-437

yellow solid

~1.3 g/cm³ (Predicted)

271.6-276° C

~595.0° C at 760 mmHg (Predicted)

n²⁰_D 1.69 (Predicted)

OVCAR-3: IC₅₀ = 0.13 µM (human); DU-145: IC₅₀ = 0.28 µM (human); LNCaP: IC₅₀ = 0.32 µM (human); ADMET: IC₅₀ = 0.33 µM; IGROV-1: IC₅₀ = 0.35 µM (human)

pK_a: 4.17 (Predicted)

RAR γ: K_i= 77 nM (human); RAR β: K_i= 2.48 µM (human); RAR α: K_i= 6.5 µM (human)

DMSO : 150 mg/mL (376.42 mM; Need ultrasonic and warming)

MFCD03106506

135411

RARγ

CD437 is a selective RARγ agonist. Growth inhibition by CD437 in these lung cancer cell lines is apparent after 2 days of treatment with 10 μM CD437. Dose-response experiments demonstrate that CD437 reduces the numbers of H460, SK-MES-1, A549, and H292 cells with 50% inhibitory values of approximately 0.5, 0.4, 3, and 0.85 μM, respectively. Treatment for 72 h with CD437 causes a strong dose-dependent growth inhibition in all melanoma cell lines. At a concentration of 5 μM CD437, only about 5 to 25% of the cells remain viable after 3 d. The concentrations of CD437 required for 50% growth inhibition (IC50) range from 10 μM for MeWo to 0.1 μM for SK-Mel-23 showing the highest sensitivity.

Tumors in CD437-treated mice stop growing, an effect that becomes already statistically significant (P<0.01) at day 13, 3 d after first administration of CD437, and is maintained for more than 3 wk after discontinuation of treatment. Further histologic analysis demonstrates marked c-fos mRNA levels at the tumor-stroma edge in CD437-treated tumors